



The Drug Utilization Review (DUR) Board Reviewed
the Following New Drugs/Classes on
September 26, 2023

Therapeutic Class	Drug Name	DURB Recommendation*
Multiple Sclerosis Agents		
	<i>Briumvi (Intravenous) Injection</i>	P/PA on PADL
Alzheimer's Agents		
	<i>Leqembi (Intravenous) Injection</i>	NP/PA on PADL
HIV/AIDS		
	<i>Sunlenca (Oral) Tablet</i>	NP/PA on PDL
	<i>Sunlenca (Subcutaneous) Injection</i>	NP/PA on PADL
	<i>Trogarzo (Intravenous) Injection</i>	NP/PA on PADL
Disease Modifier, T1DM		
	<i>Tzield (Intravenous) Injection</i>	NP/PA on PADL

*All recommendations apply to the PDL unless explicitly stated otherwise; DURB=Drug Utilization Review Board;
P=preferred; NP=non-preferred; PA=prior authorization; PDL=Preferred Drug List; PADL=Providers'
Administered Drug List